Aytu BioPharma, Inc. filings document a Nasdaq-listed pharmaceutical issuer with common stock trading under AYTU and a business centered on EXXUA, ADHD treatments, and other prescription products. Form 8-K reports furnish quarterly and annual operating results, Regulation FD investor materials, and material agreements affecting the company's financing and capital structure.
The filing record also includes definitive proxy disclosures covering board matters, executive compensation, equity awards, and shareholder voting items. Other 8-K disclosures address loan and security agreement amendments with Aytu operating subsidiaries, warrant-related accounting and stockholder-approval language, and classification issues affecting reported liabilities or equity.
Aytu BioPharma reported a sharp year-over-year decline in results for the quarter ended March 31, 2026, as it repositioned around CNS medicines and launched EXXUA. Net revenue fell to $12.4 million from $18.5 million, driven by lower ADHD and pediatric portfolio sales, partly offset by EXXUA contributing $2.4 million. The company swung to a quarterly net loss of $5.6 million from net income of $4.0 million, and posted a nine‑month net loss of $14.2 million versus net income of $6.3 million a year earlier. Cash and cash equivalents were $26.7 million, with operating cash use reduced to $1.1 million for the nine months. Aytu carried $10.4 million on its revolving credit facility and $11.6 million of term loan principal, while reclassifying $26.4 million of derivative warrant liabilities to equity, boosting reported stockholders’ equity to $35.1 million.
Aytu BioPharma reported a challenging fiscal 2026 third quarter as it ramps up the launch of EXXUA for major depressive disorder. Net revenue was $12.4 million versus $18.5 million a year earlier, reflecting lower sales in ADHD and pediatric products as resources shifted toward EXXUA and generic competition emerged.
EXXUA generated $2.4 million in its early launch quarter, while ADHD portfolio revenue was $9.1 million and pediatric revenue was $0.9 million. The company posted a net loss of $5.6 million, or $0.53 per basic share, compared with net income of $4.0 million in the prior-year quarter, influenced by a $1.3 million derivative warrant liability loss versus a prior gain.
Adjusted EBITDA was $(2.8) million, down from $3.9 million, as Aytu invested in the EXXUA launch. Cash and cash equivalents were $26.7 million at March 31, 2026. By amending and restating certain warrants, the company reduced derivative warrant liabilities by $26.4 million and increased stockholders’ equity to $35.1 million.
Aytu BioPharma, Inc. entered into amended and restated warrant agreements with institutional investors on March 31, 2026, replacing June 2023 and June 2025 prefunded and Tranche A warrants with revised beneficial ownership blockers. The new language clarifies that stockholders cannot vote to amend or change these blockers.
Previously, ambiguity around the blockers led the company, under ASC Topic 480 and ASC Topic 815, to classify the warrants as liabilities, recording a warrant liability of $18.1 million for the quarter ended September 30, 2025 and $25.2 million for the quarter ended December 31, 2025. Following the amendments, the company expects its warrant liability to decrease and its equity value to increase by the same amount.
Aytu BioPharma, Inc. shareholder Laurence W. Lytton filed an amended Schedule 13G reporting his beneficial ownership in the company’s common stock. Lytton reports beneficially owning 1,071,351 shares and warrants, representing 9.99% of the common stock outstanding.
The Lytton-Kambara Foundation reports beneficial ownership of 895,528 shares and warrants, representing 8.8% of the class. Both positions include common shares and warrants subject to a 9.99% beneficial ownership limitation, with percentages calculated using 10,188,208 shares outstanding as of November 1, 2025. The filer certifies the holdings are not for the purpose of changing or influencing control.
AYTU BioPharma, Inc. received an amended Schedule 13G showing that Investment Company, Inc., a Delaware corporation, reports beneficial ownership of 619,574 shares of AYTU common stock, equal to 5.8% of the class as of the event date 12/31/2025.
The shares are held by Special Situations Private Equity Fund, L.P., for which Investment Company, Inc. serves as investment adviser with sole voting and dispositive power. The filer certifies the position is held in the ordinary course of business and not for the purpose of changing or influencing control of AYTU.
Aytu BioPharma reported a weaker quarter as it reshapes around central nervous system medicines. For the three months ended December 31, 2025, net revenue from continuing operations was $15.2 million, down from $16.2 million a year earlier, with six‑month revenue at $29.1 million versus $32.8 million.
The company posted a net loss of $10.6 million for the quarter, compared with net income of $0.8 million in the prior‑year period. Results were heavily affected by an $8.2 million loss on derivative warrant liabilities, while loss from operations widened modestly. Six‑month net loss was $8.6 million, versus income of $2.3 million a year ago.
Cash and cash equivalents were $30.0 million, with positive operating cash flow of $3.1 million for the six months. Debt consisted of a $12.1 million term loan and $9.1 million drawn on a revolving credit facility, alongside $27.3 million of derivative warrant liabilities. The quarter also included the initial EXXUA antidepressant launch, generating $0.2 million of revenue, while the ADHD and pediatric portfolios declined.
Aytu BioPharma, Inc. announced that it issued a press release detailing its fiscal 2026 second quarter operational and financial results. The company also scheduled a public conference call and live audio webcast on February 3, 2026 at 4:30 p.m. Eastern time to discuss these results and answer questions.
The call is accessible by webcast and telephone, with replay options available on Aytu’s website and via telephone, subject to the company’s discretion. The press release containing the results is furnished as an exhibit, but is not treated as filed for liability purposes under federal securities laws.
Aytu BioPharma, Inc. filed a current report describing investor communications held on January 20, 2026. The company issued a press release titled “Aytu BioPharma Recaps Investor Day Held on January 20, 2026,” which is furnished as an exhibit. Aytu also posted an investor presentation on its website used in an investor meeting that same day.
The presentation, attached as another exhibit, includes information about the EXXUA™ (gepirone) extended-release tablets opportunity, giving investors additional detail on this product. Both the press release and the presentation are furnished, not filed, meaning they are not automatically incorporated into other securities law filings unless specifically referenced.
Aytu BioPharma, Inc. filed a current report describing investor communications held on January 20, 2026. The company issued a press release titled “Aytu BioPharma Recaps Investor Day Held on January 20, 2026,” which is furnished as an exhibit. Aytu also posted an investor presentation on its website used in an investor meeting that same day.
The presentation, attached as another exhibit, includes information about the EXXUA™ (gepirone) extended-release tablets opportunity, giving investors additional detail on this product. Both the press release and the presentation are furnished, not filed, meaning they are not automatically incorporated into other securities law filings unless specifically referenced.
Aytu BioPharma reported Q1 fiscal 2026 results showing net income from continuing operations of $1.965 million, driven by a $3.784 million non-cash gain from derivative warrant liabilities. Net revenue was $13.888 million versus $16.574 million a year ago, with the ADHD portfolio contributing $13.156 million. Gross profit was $9.186 million and loss from operations was $1.504 million as operating expenses decreased year over year.
Cash and cash equivalents were $32.630 million and total assets $124.988 million. The revolving credit facility balance was $14.873 million, and term loan debt (net) was $12.304 million. Shares outstanding were 9,911,913 as of September 30, 2025; as of November 1, 2025, common stock outstanding was 10,188,208.
The company anticipates launching EXXUA for major depressive disorder in the second fiscal quarter of 2026. During the quarter, 935,000 prefunded warrants were exercised into common stock. In June 2025, Aytu raised $16.6 million in gross proceeds via common stock and prefunded warrants to support working capital and EXXUA commercialization.
AYTU BioPharma furnished an update on its fiscal 2026 first quarter operational and financial results via a press release and scheduled a conference call and live audio webcast for November 13, 2025 at 4:30 p.m. Eastern time to discuss the results and take questions.
The webcast and telephone access details are provided in the press release, with a replay available on the company’s website and by phone at the company’s discretion. The press release is furnished as Exhibit 99.1 and is not deemed filed under the Exchange Act unless specifically incorporated by reference.